The development of a safe and effective vaccine for the novel Coronavirus is now being seen as the key way to control the pandemic. Hence, pharmaceutical companies all across the world are on a hunt to find the cure for Covid-19. Nearly 120 vaccines are currently under development, of which around ten are now in the human trial phase. Some promising vaccine candidates around the world are the CanSino adenovirus vaccine of China, Oxford University’s adenovirus vaccine, and the mRNA vaccine by Moderna and Novavax.
The Chinese biopharmaceutical company Sinovac Biotech gave the world a new hope with its inactivated vaccine ‘CoronaVac,’ when it stated that it was 99% sure of its efficacy and safety. The vaccine has already reached stage 2 of its trial, with over 1000 volunteers participating. The company is currently in preliminary talks to hold stage 3 trials in the UK, which is the final part of the process. The research and development subsidiary of Sinovac has received an amount of 15 million USD from private equity firms Vivo Capital and Advantech Capital to expedite the development of the potential vaccine. Apart from that, the firm has also been assigned a large factory for the production of the vaccine, with the aim of producing up to 100 million doses.
Furthermore, a Chinese vaccine, which is being jointly developed by the Beijing Institute of Biological Products and China National Biotec Group Co, has now successfully completed its phase II testing and is being considered to be ready for the market by the end of this year. The manufacturing line for the vaccine would be entirely disinfected and would have a production capacity of about 100 million-120 million vaccines each year. The following vaccine candidate employs a killed version of the virus that is capable of triggering an immune response. In total, five vaccines currently being developed by the Chinese companies are now being tested on humans, which is the highest in any country across the world.